Matthew Links - Concepedia

Author

Matthew Links

Also Known As

A. Parker, C. Dalrymple, C.L. Pearce, Links, Matthew, M Gray, M Links, M. LINKS, M. Links, Matthew J Links, Matthew J. Links

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

St George Hospital UNSW Sydney The University of Sydney Royal Prince Alfred Hospital St George's Hospital

About

Matthew Links is an author at St George Hospital specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	549
2	Arts	1	1	24
3	Education	1	1	24
4	Health Sciences	1	1	81
5	Nursing	1	1	24

Matthew Links

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial Nicole Mittmann, H. Au, D. Tu, JNCI Journal of the National Cancer Institute	2009	141
Learning Curve for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy—A Journey to Becoming a Nationally Funded Peritonectomy Center Tristan D. Yan, Matthew Links, Sal Fransi, Annals of Surgical Oncology Cytoreductive SurgerySurgical OncologyPerioperative Intraperitoneal ChemotherapyMedicineCancer Management	2007	140
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms Tristan D. Yan, Matthew Links, Zhiyun Xu, British journal of surgery	2006	84
Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs Robert Brown, Matthew Links Expert Reviews in Molecular Medicine Chemoprevention StrategyMeasure Drug ResistanceDrug ResistanceResistance Mutation (Virology)Anti-cancer Agent	1999	81
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer Mohammad H. Pourgholami, Michael Szwajcer, Melvin Chin, Cancer Chemotherapy and Pharmacology Advanced CancerOral AlbendazoleOncologyCancer ManagementPharmacology	2009	66
What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Belinda Thewes, Bettina Meiser, V. Duric, The Lancet Oncology Endocrine OncologyBreast OncologyOncologyEndocrine-related CancerEarly Breast Cancer	2005	64
Screening for <i><scp>ROS</scp>1</i> gene rearrangements in non‐small‐cell lung cancers using immunohistochemistry with <scp>FISH</scp> confirmation is an effective method to identify this rare target Christina Selinger, Bob T. Li, Nick Pavlakis, Histopathology	2016	61
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival Tristan D. Yan, Frank Chu, Matthew Links, European Journal of Surgical Oncology Cytoreductive SurgerySurgical OncologyNon-mucinous TumourImproved SurvivalGastrointestinal Oncology	2006	54
REVIEW OF PATIENTS WITH PERITONEAL MALIGNANCY TREATED WITH PERITONECTOMY AND HEATED INTRAPERITONEAL CHEMOTHERAPY Reema Hadi, Vanessa Saunders, Olga Utkina, ANZ Journal of Surgery	2006	38
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses Eun Young Kang, Dane Cheasley, Cécile Le Page, Modern Pathology Tumor HeterogeneityMedicineGynecologyPathologyTp53 Mutation Status	2020	38

Page 1